Treatment of Pancreatic Cancer: Current Limitations, Future Possibilities
March 01, 1996
Drs. Blackstock, Cox, and Tepper have outlined some salient aspects of the management of pancreatic cancer. I agree with most of their comments, and will address some issues from my own perspective, colored largely by a symposium on cancer of the pancreas held in Newport, Rhode Island, in July 1994. This gathering of a large nucleus of investigators with a major interest in pancreatic cancer provided some additional insights that I will explore in my commentary and that largely complement the points made by Blackstock et al. Among other issues, my remarks will focus on: (1) the use of molecular markers for diagnosis and treatment, (2) preoperative chemoradiation, and (3) some surgical considerations that still generate controversy; ie, the extent of resection.